Advertisement

Topics

Frontier Pharma: Hematological Disorders Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need [Report Updated: 01082017] Prices from U

05:39 EDT 11 Sep 2017 | BioPortfolio Reports

Frontier Pharma: Hematological Disorders Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need

Summary

The hematological disorders therapy area encompasses nonmalignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three categories red blood cell disorders, bleeding disorders and immune cell disorders of which red blood cell disorders are characterized by significant unmet need related to few effective treatment options and poor prognosis. As such, they are the primary focus of the report.

Historically, the hematological disorders therapy area has suffered from a lack of funding for research, which has contributed to the level of unmet need, although there have been instances in which funding for an indication has resulted in a strong return on investment. A notable example is the approval of Soliris in 2007, which is used to treat the orphan disease paroxysmal nocturnal hemoglobinuria. Soliris is one of only two marketed treatment options for PNH and is forecast to generate annual revenue of over $3 billion by the end of 2017, rising to $5.5 billion in 2023.

The report assesses firstinclass innovation in the hematological disorders pipeline, highlighting key trends in the pipeline, and emerging treatment classes. There are 92 firstinclass products in development in this therapy area; which account for 28% of products in the overall pipeline for which there is a disclosed molecular target, and act upon 71 unique individual molecular targets.

These firstinclass targets in the pipeline are numerous and varied, with many of them having been shown to be promising in early stage studies. Immune components are the most common, accounting for a total of 21 firstinclass developmental programs, closely followed by DNA regulators. These target categories combined account for the majority of red blood cell disorder pipeline therapies, although iron regulator programs alone also appear frequently.

Scope

With 488 products in active development, the pipeline for hematological disorders is modestly sized. Does current pipeline innovation hold the potential to affect the future hematological disorders market?
There are 92 firstinclass products in the hematological disorders pipeline, which act on a novel molecular target which is not present in an approved product across any indication the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years and a large number of firstinclass products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which firstinclass programs which have not yet been involved in a licensing or codevelopment deal appear to be particularly promising?

Reasons to buy

Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
Visualize the composition of the hematological disorders market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the hematological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological disorders to overcome the overwhelming level of unmet need.
Assess the therapeutic potential of firstinclass targets. Using a proprietary matrix, firstinclass products have been assessed and ranked according to clinical potential. Promising earlystage targets have been reviewed in greater detail.
Identify commercial opportunities in the hematological disorders deals landscape by analyzing trends in licensing and codevelopment deals and analyzing a curated list of hematological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Original Article: Frontier Pharma: Hematological Disorders Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need [Report Updated: 01082017] Prices from U

NEXT ARTICLE

More From BioPortfolio on "Frontier Pharma: Hematological Disorders Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need [Report Updated: 01082017] Prices from U"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...